

INDIAN INCOME TAX RETURN ACKNOWLEDGEMENT

[Where the data of the Return of Income in Form ITR-1(SAHAJ), ITR-2, ITR-3, ITR-4(SUGAM), ITR-5, ITR-6, ITR-7 filed and verified]
(Please see Rule 12 of the Income-tax Rules, 1962)

Assessment
Year
2023-24

PAN	AASCA1841Q		
Name	ASSTON PHARMACEUTICALS PRIVATE LIMITED		
Address	OFFICE NO B-225, PLOT NO 42A, SECTOR NO 11,, BALAJI BHAVAN, CBD BELAPUR, NAVI MUMBAI , THANE , 19- Maharashtra, 91-INDIA, 400614		
Status	7-Private company	Form Number	ITR-6
Filed u/s	139(1)-On or before due date	e-Filing Acknowledgement Number	395361431091023

Taxable Income and Tax Details	Current Year business loss, if any	1	0
	Total Income	2	1,06,15,700
	Book Profit under MAT, where applicable	3	0
	Adjusted Total Income under AMT, where applicable	4	0
	Net tax payable	5	26,71,759
	Interest and Fee Payable	6	3,20,480
	Total tax, interest and Fee payable	7	29,92,239
	Taxes Paid	8	29,92,239
(+) Tax Payable /(-) Refundable (7-8)	9	0	
Accreted Income and Tax Detail	Accreted Income as per section 115TD	10	0
	Additional Tax payable u/s 115TD	11	0
	Interest payable u/s 115TE	12	0
	Additional Tax and interest payable	13	0
	Tax and interest paid	14	0
	(+) Tax Payable /(-) Refundable (13-14)	15	0

This return has been digitally signed by ASHISH NARAYAN SAKALKAR in the capacity of Director having PAN AUSPS2933G from IP address 110.226.182.226 on 09-Oct-2023 16:22:11 at THANE (Place) DSC SI.No & Issuer 3070868 & 435724978917CN=XtraTrust Sub CA 2022,OU=Certifying Authority,O=XtraTrust DigiSign Private Limited,C=IN

System Generated

Barcode/QR Code



AASCA1841Q06395361431091023af9b8f2ba12ff1da1c88815fb71236b9a9a88ea2

DO NOT SEND THIS ACKNOWLEDGEMENT TO CPC, BENGALURU

A.Y. 2023-2024**Name** : ASSTON PHARMACEUTICALS PRIVATE LIMITED**Previous Year** : 2022-2023**Address** : OFFICE NO B-225, PLOT NO 42A, SECTOR NO 11,**PAN** : AASCA 1841 QBALAJI BHAVAN
CBD BELAPUR
NAVI MUMBAI, THANE - 400 614**Status** : Domestic Company**D. O. I.** : 16-Apr-2019

Opted Tax u/s 115BAA

Statement of Income

	Rs.	Rs.	Rs.
■ Profits and gains of Business or Profession			
<i>Business-1</i>			
Net Profit Before Tax as per P & L a/c		1,07,47,924	
Add: Inadmissible expenses & Income not included			
Depreciation debited to P & L a/c		10,57,307	
<i>Adjusted Profit of Business-1</i>		1,18,05,231	
Total income of Business and Profession		1,18,05,231	
Less: Depreciation as per IT Act	3	11,89,536	
<i>Income chargeable under the head "Business and Profession"</i>			1,06,15,695
■ Total Income			
Total income rounded off u/s 288A			1,06,15,700
<i>Tax on total income</i>			23,35,454
Add: Surcharge			2,33,545
Tax with Surcharge			25,68,999
Add: Cess			1,02,760
Tax with surcharge and cess			26,71,759
TDS / TCS	1		12,112
Balance Tax			26,59,647
Interest u/s 234B		1,86,172	
Interest u/s 234C		1,34,308	3,20,480
Net tax payable			29,80,127
Self-assessment tax paid	2		29,80,127
■ Balance tax payable			0

Schedule 1*TDS as per Form 16A***Deductor, TAN**Bank Of Maharashtra Mumbai City Regional Office, TAN-
MUMB12639E

<u>TDS deducted</u>	<u>TDS claimed in current year</u>	<u>Gross receipt offered</u>
12,112	12,112	1,21,071

Schedule 2**Self Assessment tax paid****Name of the Bank and BSR Code**

ICICI Bank - 6390009

<u>Date of deposit</u>	<u>Challan Sl.no.</u>	<u>Amount paid</u>
09-Oct-23	16891	29,80,127

Bank A/c: BANK OF MAHARASTRA 60347910757 IFSC: MAHB0000089

For ASSTON PHARMACEUTICALS PRIVATE LIMITED

Date : 09-Oct-2023

Place : THANE

Authorised Signatory

ASSTON PHARMACEUTICALS PVT. LTD
BALANCE SHEET AS AT 31ST MARCH 2023

Sr no	Particulars	Note No.	Figures as at the end of the current reporting period as on 31.03.23	Figures as at the end of the Previous reporting period
			(Rs.in Hundreds)	(Rs.in Hundreds)
	1	2	3	4
I.	EQUITY AND LIABILITIES			
(1)	Shareholders' Funds			
	(a) Share Capital	1	70,000.00	70,000.00
	(b) Reserves and Surplus	2	1,00,571.59	23,081.58
	(c) Money received against		-	-
(2)	Share Application Money			
(3)	Non - Current Liabilities			
	(a) Long Term Borrowings	3	3,72,375.13	2,52,295.63
	(b) Deferred Tax Liabilities (Net)		2,137.85	1,805.05
	(c) Other Long Term Liabilities		-	-
	(d) Long - Term Provisions		-	-
(4)	Current Liabilities			
	(a) Short Term Borrowings		1,51,663.44	75,664.18
	(b) Trade Payables		5,57,671.77	4,56,204.21
	(c) Other Current Liabilities	4	35,892.15	7,551.61
	(d) Short - Term Provisions	5	1,444.00	6,062.00
	TOTAL		12,91,755.93	8,92,664.26
II.	ASSETS			
(1)	Non - Current Assets			
	(a)(i) Property, Plant & Equipment	6	1,02,280.50	87,776.01
	(ii) Intangible Assets		-	-
	(iii) Capital Work-in-Progress		-	-
	(iv) Intangible Assets under Development		-	-
	(b) Non - Current Investments		-	-
	(c) Deferred Tax Assets (Net)		-	-
	(d) Long - Term Loan and Advances		-	-
	(e) Other Non - Current Assets		-	-
(2)	Current Assets			
	(a) Current Investments		-	-
	(b) Inventories		1,50,083.49	50,333.49
	(c) Trade Receivables	7	7,98,609.63	5,56,689.84
	(d) Cash and Cash Equivalents		12,369.59	13,681.10
	(e) Short Term Loans and Advances	8	41,399.00	64,709.70
	(f) Other Current Assets	9	1,87,013.71	1,19,474.12
	TOTAL		12,91,755.93	8,92,664.26
III.	NOTES FORMING PART OF THE FINANCIAL STATEMENTS			

The accompanying notes forms an integral part of financial statements.
As per our report of even date attached.

FOR POOJA V. RAVANI & CO.
CHARTERED ACCOUNTANTS

P.V. Ravani
POOJA V. RAVANI
(PROPRIETOR)
MEMBERSHIP NO. 163629
FRN : 140450W

DATE: 11/09/2023
MCA UDIN : 23163629BGXPBQ6029
IT UDIN : 23163629BGXPBP2058

FOR ASSTON PHARMACEUTICALS PVT. LTD.

Ashish Narayan Sakalkar
ASHISH NARAYAN SAKALKAR
Director
DIN NO: 06601011

Saili Jayaram More
SAILI JAYARAM MORE
Director
DIN NO: 02691527



ASSTON PHARMACEUTICALS PVT. LTD
PROFIT & LOSS STATEMENT
FOR THE YEAR ENDED 31ST MARCH, 2023

Sr no	Particulars	Note No.	Figures as at the end	Figures as at the end
			of the current	of the Previous
			reporting period as on	reporting period
			31.03.23	
			(Rs.in Hundreds)	(Rs.in Hundreds)
I.	Revenue from Operations		6,61,004.88	10,13,633.28
II.	Other Income	10	16,718.53	23,867.34
III.	Total Revenue (I + II)		6,77,723.42	10,37,500.62
IV.	Expenses :			
a)	Cost of Materials Consumed		-	-
b)	Purchases of stock-in-trade		3,70,234.41	5,95,292.09
c)	Changes in Inventories of Finished Goods Work-in-Progress and stock-in-trade	11	(2,25,091.11)	74,914.92
d)	Employee Benefits Expense	12	55,452.67	56,764.00
e)	Finance Costs	13	57,037.83	26,280.88
f)	Depreciation and Amortization Expense		10,573.07	4,803.64
g)	Other Expense	14	1,76,696.19	2,64,191.10
	Total Expenses		4,44,903.07	10,22,246.62
V.	Profit Before Exceptional and Extraordinary Items and Tax (III - IV)		2,32,820.35	15,253.99
VI.	Exceptional Items			
VI.	Profit Before Extraordinary Items and Tax (V- VI)		2,32,820.35	15,253.99
VII.	Extraordinary Items (Containers Burned in importing Country)	15	1,25,341.11	
VIII.	Profit Before Tax (VII - VIII)		1,07,479.24	15,253.99
IX.	Tax Expenses :			
	(1) Current Tax		29,656.43	2,972.27
	(2) Deferred Tax		332.80	1,068.00
X.	Profit/ (Loss) for the period from continuing operations.		-	-
XI.	Profit/(Loss) for the period		77,490.01	11,213.72
XII.	Earnings per equity share :			
	(1) Basic		0.11	0.02
	(2) Diluted			
XIII.	NOTES FORMING PART OF THE FINANCIAL STATEMENTS			

The accompanying notes forms an integral part of financial statements.
As per our report of even date attached.

FOR POOJA V. RAVANI & CO.
CHARTERED ACCOUNTANTS



P.V. Ravani
POOJA V. RAVANI
(PROPRIETOR)
MEMBERSHIP NO. 163629
FRN : 140450W

DATE : 11/09/2023
MCA UDIN : 23163629BGXPBQ6029
IT UDIN : 23163629BGXPBP2058

FOR ASSTON PHARMACEUTICALS PVT. LTD.

A. Sakalkar
ASHISH NARAYAN SAKALKAR
Director
DIN NO: 06601011



S. Jayaram More
SAILI JAYARAM MORE
Director
DIN NO: 02691527

ASSTON PHARMACEUTICALS PVT. LTD

**CASH FLOW STATEMENT (AS-3)
FOR THE YEAR ENDED 31.03.2023**

Particulars	Note	Rs	Rs
NET PROFIT AS PER PROFIT & LOSS ACCOUNT			77490
Add Back:			
Depreciation on Fixed Assets	6	10573.07	
DTL		332.80	
Interest Paid	13	57037.83	67943.70
Less: Taxes Paid			0
CASH GENERATED BEFORE WORKING CAPITAL CHANGES			145433.7164
CHANGE DUE TO WORKING CAPITAL			
Add:			
Increase in Creditors		1,01,467.56	
Increase in Short Term Borrowings		75,999.26	
Increase in Other Current Liability	4	28,340.54	
Decrease other short term loans & Advances	8	23,310.70	2,29,118.05
Less :			
Decrease in Short Term Provisions	5	4,618.00	
Increase in Debtors		2,41,919.79	
Increase in Stock		99,750.00	
Increase in Other Current Asset	9	67,539.59	4,13,827.38
CASH GENERATED FROM OPERATIONS			
A NET CASH FLOW FROM OPERATING ACTIVITIES			(39,275.61)
Purchase of Fixed Assets	6	-25077.57	
B NET CASH FLOW FROM INVESTING ACTIVITIES			(25,077.57)
Issue of Equity Shares		-	
Long Term Borrowings obtained	3	1,20,079.50	
Interest Paid	13	-57037.83	63041.67
C NET CASH FLOW FROM FINANCING ACTIVITIES			63,041.67
NET CASH & CASH EQUIVALENTS FOR F.Y YEAR ENDED 31.03.2022 (A+B+C)			-1,311.51
Add: Opening Balance of Cash & Cash Equivalents			13,681.10
NET CASH & CASH EQUIVALENTS FOR F.Y YEAR ENDED 31.03.2022 (A+B+C)			12,369.60

FOR POOJA V. RAVANI & CO.
CHARTERED ACCOUNTANTS




 POOJA V. RAVANI
 (PROPRIETOR)
 MEMBERSHIP NO. 163629
 FRN : 140450W

FOR ASSTON PHARMACEUTICALS PVT. LTD.


 Director



NOTE 1

Note of Share Capital annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.23		31.03.22	
	Number	Amount (in Hundreds)	Number	Amount (in Hundreds)
1) Authorised Capital Equity shares of Rs. 10/- each	10,00,000.00	1,00,000.00	10,00,000.00	1,00,000.00
2) Issued, Subscribed and paid up Equity shares of RS.10/- each fully paid	7,00,000.00	70,000.00	7,00,000.00	70,000.00

Particulars	Equity Shares	
	Number	Amount (Rs in Hundreds)
Shares outstanding at the beginning of the year	7,00,000.00	70,000.00
Shares Issued during the year	-	-
Shares bought back during the year	-	-
Shares outstanding at the end of the year	7,00,000.00	70,000.00

Details of Shares held by each Shareholder holding more than 5% shares :

Classes of shares/ Name of Shareholders	As at 31st March 2023		As at 31st March 2022	
	No of Shares held	% of Shares held	No of Shares held	% of Shares held
Equity Shares				
Ashish Sakalkar	3,50,000.00	50.00%	3,50,000.00	50.00%
Sailli More	3,50,000.00	50.00%	3,50,000.00	50.00%
	7,00,000.00	100.00%	7,00,000.00	100.00%

Details of Shares held by Promoters

Classes of shares/ Name of Shareholders	As at 31st March 2023		As at 31st March 2022	
	No of Shares held	% of Shares held	No of Shares held	% of Shares held
Equity Shares				
Ashish Sakalkar	3,50,000.00	50.00%	3,50,000.00	50.00%
Sailli More	3,50,000.00	50.00%	3,50,000.00	50.00%
	7,00,000.00	100.00%	7,00,000.00	100.00%

NOTE 2

Note of Reserves & Surplus annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	As at 31/3/2023 (Rs.)	As at 31/3/2022 (Rs.)
Profit and Loss A/c		
Opening Balance	23,081.58	11,867.85
: Additions during the year	77,490.01	11,213.72
: Utilised/Transferred during the year	-	-
Closing Balance	1,00,571.59	23,081.58

H. Sakalkar *Sailli More*



NOTE 3

Note of Long term Borrowings annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.2023	31.3.2022
Loan From Bank Of Maharashtra PCFC 60348143129	1,51,345.46	1,50,779.59
AU Small Finance Bank Loan A/c	-	68,917.55
Loan From Bank Of Maharashtra 60355787370	-	883.52
Axis Bank	-	16,836.76
Bajaj Finance	8,297.81	13,847.57
Ashv Finance Ltd	22,862.50	
Axis Bank	17,184.68	
CLIX Capital Services	18,753.24	
Herofin Corp	13,995.07	
Kotak Mahindra Bank	76,151.73	
Tata Capital Finance	18,426.70	
Unity Small Finance	9,342.60	
CAR LOAN	25,914.00	
Loan From Directors	10,101.34	1,030.64
TOTAL	3,72,375.13	2,52,295.63

NOTE 4

Note of Other Current Liabilities annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.2023	31.3.2022
TDS PAYABLE	5,884.26	6,079.34
Outstanding Loan Principal	472.59	-
INCOME TAX TAX PAYABLE	29,535.30	1,472.27
TOTAL	35,892.15	7,551.61

NOTE 5

Note of Provisions annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.2023	31.3.2022
SALARY PAYABLE	1,444.00	6,062.00
TOTAL	1,444.00	6,062.00

H. Aravind
3/2023



NOTE 6 OF FIXED ASSETS AND DEPRECIATION UNDER COMPANIES ACT, 2013 AS ON 31.03.2023

DESCRIPTION							NET BLOCK	
	Cost as at 01.04.22	Additions during the year	Cost as at 31.03.2023	Provided upto 01.04.2022	Depreciation Provided during the year	Total upto 31.03.2023	W.D.V. as at 31.03.2023	W.D.V. as at 31.03.2022
TANGIBLE FIXED ASSET								
Fixture & Furniture	280.00	-	280.00	133.09	38.04	171.12	108.88	146.91
Computer & Accessories	890.00	-	890.00	470.36	167.85	638.22	251.78	419.64
Building (office)	93,165.00	-	93,165.00	5,955.54	4,360.47	10,316.01	82,848.99	87,209.46
Motor Vehicle		25,077.57	25,077.57	-	6,006.71	6,006.71	19,070.86	-
TOTAL	94,335.00	25,077.57	1,19,412.57	6,558.99	10,573.07	17,132.06	1,02,280.50	87,776.01

H. Maus
smore



NOTE 7

Note of Trade Receivables annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.2023	31.3.2022
1) Sundry Debtors For Goods (O/s Less than six months)	7,98,609.63	5,56,689.84
a. Secured Considered Good	-	-
b. Unsecured Considered Good	-	-
c. Considered Doubtful	-	-
TOTAL	7,98,609.63	5,56,689.84

NOTE 8

Note of Short Term Loans & Advances annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.2023	31.3.2022
<u>Loans & Advances</u>	-	-
GST BALANCE	41,399.00	64,425.97
TCS ON GOODS	-	283.73
	41,399.00	64,709.70

NOTE 9

Note of Other Current Assets annexed to & forming part of Balance Sheet as at 31.03.2023

Particulars	31.03.2023	31.3.2022
FD WITH BANK	67,339.59	-
Other Current Asset	1,19,674.12	1,19,474.12
	1,87,013.71	1,19,474.12

Handwritten signature
smore



NOTE 10

**Note of Other Income annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2023**

Particulars	31.03.2023	31.03.2022
Export Incentives	9,246.42	21,067.70
Foreign Exchange Gains	-	2,429.00
Discount Received	2,384.48	352.00
Interest on FD	1,210.71	18.64
Interest on Equilization Scheme Benefit	3,876.92	
TOTAL	16,718.53	23,867.34

NOTE 11

**Note of details of Stock of Finished Goods & Consumables annexed to &
forming part of Profit & Loss Account for the year ended on 31.03.2023**

Particulars	31.03.23	31.03.22
Stock of Finished Goods & Consumables at the beginning of the Period	50,333.49	1,25,248.41
Abnormal Loss of stock due to Containers Burned in imported Country	1,25,341.11	
Stock of Finished Goods & Consumables at the end of the Period	1,50,083.49	50,333.49
Total	(2,25,091.11)	74,914.92

NOTE 12

**Note of Employee Benefits Expenses annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2023**

Particulars	31.03.23	31.03.22
Directors Remuneration	36,050.00	36,050.00
Salary	19,402.67	20,714.00
Total	55,452.67	56,764.00

*Shakun
Shore*



NOTE 13

Note of Finance Expenditure annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2023

Particulars	31.03.2023	31.03.2022
Bank Charges	618.76	2,221.38
Bank Interest	51,891.20	23,234.83
Bank Processing Fees	4,527.87	824.66
	57,037.83	26,280.88

NOTE 14

Note of Other Expenditure annexed to & forming part of
Profit & Loss Account for the year ended on 31.03.2023

Particulars	31.03.2023	31.03.2022
Audit Fees	90.00	
Clearing & Forwarding Charges	82,100.22	1,30,872.77
Courier Charges	491.60	55.97
Car Expenses	485.74	
Discount Given	105.78	
Electricity Charges	393.60	386.75
Freight & Forwarding Charges	995.15	1,899.73
Ful & Petrol Expenses	308.88	-
Insurance Expenses	3,638.03	244.08
Keyman Insurance Policy	2,751.76	
Interest on TDS	41.97	327.46
Labour Charges	65,039.02	94,148.62
Licenses Fees	363.08	2,538.62
Misc Expenses		32.54
Membership & Registration Fees		29.99
Marketing Expenses		529.00
Office Repairs & Maintenance Expenses	860.84	742.60
Office Expenses	757.42	353.50
Other Expenses	478.45	482.00
Pramotional Expenses	1,132.89	1,290.78
Packing & Forawrding Charges	35.75	444.96
Printing & Stationery	1,911.18	551.56
Professional Fees	1,023.00	665.00
Roc Fees & Expenses	2,322.50	37.00
Refreashment Expenses	1,803.12	130.08
Stampduty exp	338.25	1,317.00
Travelling Expenses	7.56	1,949.35
Telephone Expenses	107.24	137.72
Testing Charges	609.75	1,055.55
Transport & Hamali Charges	8,065.70	6,771.73
Registration Charges	156.91	17,151.75
Valuation Charges	70.80	
FDA Fees	210.00	45.00
Total	1,76,696.19	2,64,191.10

Harsh
More



Note : 15

The company exported medicine containers to Conakry Guinea against order received from them.

There had been sudden change in the government policy of Guinea for usage of medicine imported from all over country.

The Government of Guinea had imposed restriction on usage of medicine imported from all country except franch.

The Government of Guinea allowed Compulsory use of only franch medicine.

Due to the sudden change, all Indian imported medicines containers were lying on guinea port for more than eight months and order given to burn these containers without any intimation to our company. Even the shipping line could not intervene for above period

Original bill of lading was still laying with company.

Due to this event, company incurred abnormal loss of stock of Rs 1,25,34,100/- which is debited to profit and loss account as extraordinary item as container burned in imported country.

8/10/2011
H. Anand



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year: 2022-2023)

NOTES ON ACCOUNTS & ACCOUNTING POLICIES FOR THE YEAR ENDED 31st MARCH 2023.

1. A) SIGNIFICANT ACCOUNTING POLICIES

A) Basis for preparation of Financial Statements (AS 1)

These financial statements have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) including the Accounting Standards notified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013.

The financial statements have been prepared under the historical cost convention on accrual basis.

B) Inventories (AS 2):

Inventories are valued at lower of cost or Net realizable value. Cost is computed on the basis of cost of purchase under "Fist-In- First-Out" basis.

C) Contingencies & Events Occurring After B/S Date (AS 4)

No Significant Events as mentioned in AS-4 occurred between the balance sheet date and the date of Approval of Financial Statements, which had a significant Effect on the Financial Statement.

D) Prior Period Items& Change in Accounting Policies (AS 5)

During the year, there were no transactions relating to the prior period which require a separate disclosure and there was no material change in the accounting policies, which requires a separate disclosure since its first years of operation.



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year 2022-2023)

E) Depreciation (AS 6)

Depreciation has been provided on the Fixed Assets, on WDV basis in accordance with the companies Act, 2013 at the rates specified in schedule II of the Companies Act, 2013.

F) Income Recognition (AS 9)

Revenue from Export sales, including export incentives, are recorded on the occurrence of sale. Income in the form of discounts & other credits allowed by the supplier company are recorded when the supplier company allows it by issuing a credit note/other relevant document. Interest on FD are recorded on accrual basis. However interest on scheme benefits are recorded on receipt basis.

G) Fixed Assets (AS 10)

Fixed assets are carried at cost of acquisition (including directly attributable costs such as freight, installation, Stamp duty, Registration Charges, etc.) less accumulated depreciation.

H) Investments (AS 13)

Investments in fixed deposits are recorded at actual cost incurred by the company. There is no any other investment made by the company except fixed deposit.

I) Employee Benefits (AS 15)

The company has neither quantified nor provided for Employee retirement benefits.

J) Borrowing Cost (AS 16)

Borrowing cost are recognized as an expense in the period in which they are incurred.

*Small
always*



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year 2022-2023)

K) Related Party Disclosure (AS 18)

In pursuant to disclosure requirement as prescribed under the Accounting Standard (AS-18) 'Related Party Disclosure' issued by the Council of the Institute of Chartered Accountants of India, following disclosure is made in respect of the transactions with the related party.

Name of the Related Party	Nature of Relation	Nature of transaction	(Rs. In Hundreds)
Ashish Sakalkar	Director	Director's Remuneration	Rs. 18,025/-
Saili More	Director	Director's Remuneration	Rs. 18025/-
Raj More	Son of Director	Salary	Rs: 6,000/-
Vishakha Sakalkar	Wife of Director	Salary	Rs: 6,000/-
Asston International	Director is a partner In firm	Loan Given	Rs. 119,674.12/-

L) Earning Per Share (AS 20)

(Rs. In Hundreds)

	2022-2023	2021-2022
Net Profit/(Loss) for the year	77,490.01/-	11,213.72/-
No.of Shares	7,00,000	7,00,000
Earning Per Share	0.11/-	0.02/-

Ashish Sakalkar
Saili More



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year 2022-2023)

M) Impairment of Assets (AS28)

During the year no asset is impaired as mentioned in AS 28 and hence question of transferring loss to Profit & Loss Account as required by AS 28 does not arise.

N) Cash Flow Statement (AS-3):

Cash Flow Statement are prepared using indirect Method as per AS-3 issued by ICAI. whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities of the Company are segregated.

O) Foreign exchange transactions

The Company is exposed to foreign currency transactions and receives foreign currency revenues due to Export Sale. Foreign exchange transactions are recorded using the exchange rates prevailing on the dates of the respective transactions. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the statement of profit and loss for the year.

P) Taxation

Provision for tax is made for both Current tax and Deferred Taxes. Current Income Tax is determined on the profits for the year in accordance with the provisions of Section 115BAA of Income Tax Act, @ 22% under new scheme of taxation.



ASSTON PHARMACEUTICALS PVT. LTD
(Accounting Year 2022-2023)

Q) Provisions, Contingent Liabilities and Contingent Assets (AS 29)

Contingent liabilities and contingent assets are neither recognised nor disclosed in the financial statement. Further as on 31st March, 2023 there are no contingent liabilities which should have been disclosed in the financial statements.

FOR ASSTON PHARMACEUTICALS PVT. LTD.



H. Akansh
Smare
Director

Date: 11/09/2023
Place: Dombivli

POOJA V. RAVANI & CO.
Chartered Accountants
Firm Reg.No.140450W

P.V. Ravani
(Proprietor)
M. No. 163629

